Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple device improve dialysis? small study tests HemoCept

NCT ID NCT07217470

Knowledge-focused Sponsor: HemoCept Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed pilot study tested whether the HemoCept device can accurately measure fluid removal during dialysis in 26 adults with end-stage kidney disease. Researchers compared device readings before and after dialysis to changes in dry weight. The goal is to see if this non-invasive tool could help doctors better manage fluid balance during treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HemoCept device
What this could lead to
If successful, this could lead to a non-invasive way to monitor fluid removal during dialysis, improving treatment precision.
What could go wrong
This is a small pilot study with only 26 participants, so results may not apply to everyone. The device is still experimental and may not prove accurate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

26 people

The number who actually took part.

Started

Aug 2025

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects between (and including) the ages of 18 and 75 and who meet all the Inclusion/Exclusion criteria

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject or representatives must have voluntarily signed the informed consent form before any study related procedures * Subjects can be any gender, but must be between (and including) 18 and 75 years of age * Subject has been on dialysis for more than 90 days and has been diagnosed with end stage kidney disease * Subject is able and willing to provide informed consent and HIPAA authorization. * Subject is able and willing to meet all study requirements * Subject is able to place electrodes on bilateral deltoids and above the pant line on the waist. Exclusion Criteria: * Subject is pregnant, breast-feeding, or intends to become pregnant during the course of the study. * Subject has a personal medical history that includes: Long Q-T syndrome, Cardiac channelopathies, genetic heart defects, Seizures, Acute untreated blood clotting disorders or acute untreated bleeding disorders * Subject has had a heart transplant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESRD (end-stage renal disease) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESRD (end-stage renal disease)

Contacts and locations

Locations

  • Sierra Nevad Specialty Care

    Reno, Nevada, 89511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.